FDA panel rejects Sonablate 450 HIFU device for prostate cancer
This article was originally published in Clinica
A US FDA advisory panel has almost unanimously rejected SonaCare Medical’s Sonablate 450 high-intensity focused ultrasound (HIFU) device, which is designed to treat recurrent prostate cancer after radiotherapy. The panelists voted that the data with the device was not good enough to support a positive risk-benefit profile, but they suggested the company could improve their trial design and provide more data in the future.
You may also be interested in...
All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.